Delivering the right medicine, to the right patient, at the right time.

Clinigen is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines.

1. Culture: Develop and retain talented people

2019 Progress

  • 29 employees completed the Clinigen Management Academy training program
  • Long service recognition awards introduced globally
  • Launched online survey tool for employees, providing weekly engagement data

Performance Metrics

  • Employee engagement score: 7.1

2020 Objectives

  • Launch a bespoke leadership development program
  • Introduce a global employee wellbeing initiative
  • Improve engagement and retention levels
2. Technology: Upgrade technology platform to drive organic growth

2019 Progress

  • Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
  • Launch of Clinigen Direct, a new digital service offering for HCPs to source hard to access medicines
  • Continued implementation of Clinigen One ERP modules

Performance Metrics

  • Number of products available on Cliniport and Clinigen Direct: >1,800

2020 Objectives

  • Complete implementation of Clinigen One ERP
  • Increase number of programs and products available on Cliniport and Clinigen Direct
  • Embed Cliniport and Clinigen Direct functionality including extended real world data (‘RWD’) capability
3. Customer: Expand and embed a global community of HCPS and opinion leaders

2019 Progress

  • Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
  • Launch of Clinigen Direct, a new digital service offering for HCPs to source hard to access medicines
  • Building out US commercial infrastructure following acquisition of Proleukin
  • EU MSL capability through acquisition of iQone will help interaction with HCP customers

Performance Metrics

2020 Objectives

  • Increase number of users and amount of activity through Cliniport and Clinigen Direct
  • Expand MSL and commercial capability in the US and the EU
  • Drive Key Opinion Leader (‘KOL’), hospital pharmacist and pharmacy group engagement across markets
4. Business: Expand portfolio of global, regional and licensed assets

2019 Progress

  • Acquisition of Proleukin and Imukin strengthen our offering in Commercial Medicines
  • Approval of Foscavir for the treatment of HHV-6 in Japan
  • Launch of Melatonin demonstrating further success of the UL2L development pipeline
  • Exclusive licensing agreement signed with GC Pharma in Japan. Clinigen’s first such agreement in Japan

Performance Metrics

2020 Objectives

  • Further conversion of UL2L pipeline
  • Internationalisation of developed commercial product portfolio
  • Continue to search for selective acquisitions
  • Conversion of MAPs to regional licensing opportunities
5. Business: Become the 'go to' global leader in ethical access to unlicensed medicines

2019 Progress

  • Acquisition of CSM reinforces links between Clinical Services and Unlicensed Medicines
  • Acquisition of iQone provides MSL capability, a key differentiator in the Managed Access business within Unlicensed Medicines from its competitors
  • Increase in number of MAPs and exclusive Global Access client supply agreements
  • Launch of Clinigen Direct, a new digital service offering for HCPs to source hard to access medicines

Performance Metrics

2020 Objectives

  • Expand and deepen our client base in Managed Access
  • Develop our portfolio of exclusive supply agreements
  • Build an excellence in Customer Services
  • Leverage Group sourcing and procurement capability
6. Business: Extend global footprint into remaining key markets

2019 Progress

  • Acquisition of Proleukin provides an ideal platform to expand existing footprint in the US
  • Acquisition of CSM provides important EU infrastructure
  • Acquisition of iQone helps support Clinigen’s Commercial Medicines portfolio in key EU markets
  • Partnership agreement with Accord signed to supply and distribute Cardioxane and Savene in Poland

Performance Metrics

2020 Objectives

  • Further partnership agreements signed to expand geographical reach, particularly in the LATAM and the Middle East
  • Further expansion of commercial infrastructure in US and EU
7. Business: Link to Businesses to realise synergistic opportunities and increase pharmaceutical customer base

2019 Progress

  • Acquisition of CSM increases the size of the customer base at an early stage of product lifecycle and additional capabilities have enhanced proposition across the Group’s three business operations
  • Acquisition of iQone provides capability to partner with pharmaceutical and biotech companies to commercialise products earlier in the lifecycle and support partner company products
  • Creation of Group Heads of Business Development Network to work more effectively and realise links between the businesses

Performance Metrics

  • Number of top 50 pharmaceutical companies who have worked with all three business operations:

2020 Objectives

  • Embed a culture that seeks to maximise value through extending product commercial relationships through the lifecycle
  • Increase the number of top 50 companies working with all business operations
  • Increase the number of companies working with at least two business operations
  • Ensure alignment of objectives across business divisions and support functions with scorecards developed at each level